Anti-fibrotic composition for preventing or treating fatty liver or liver cirrhosis, containing jujube polysaccharides as active ingredient

A jujube polysaccharide composition effectively inhibits fibrosis-related markers and reduces hepatic steatosis and inflammation, addressing the lack of treatments for MASLD and related liver diseases.

WO2026177544A1 Publication Date: 2026-08-27IND ACADEMIC COOPERATION FOUND JEJU NAT UNIVERSTIY
0 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2026/002860
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-02-20
Filing Date
2026-02-19
Publication Date
2026-08-27

AI Technical Summary

Technical Problem

There are no effective treatments for metabolic dysfunction-associated steatotic liver diseases (MASLD) such as non-alcoholic fatty liver disease, which can progress to fibrosis and cirrhosis, and existing medications for metabolic syndromes like abdominal obesity, hyperlipidemia, and diabetes do not directly address these conditions.

Method used

A composition containing jujube polysaccharides is developed, prepared through a process involving concentration, protein removal, ethanol precipitation, and freeze-drying, which inhibits fibrosis-related mRNA and protein expression induced by TGF-β1 in hepatic stellate cells, reducing hepatic steatosis and inflammation.

Benefits of technology

The jujube polysaccharide composition significantly inhibits fibrosis-related markers and reduces body fat mass, hepatic steatosis, and inflammation, offering a potential treatment for antifibrosis, fatty liver, and liver cirrhosis.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to an anti-fibrotic composition for preventing or treating fatty liver or liver cirrhosis, the composition containing jujube polysaccharides as an active ingredient. The jujube polysaccharide-containing composition according to the present invention can significantly inhibit the expression of fibrosis-related mRNAs (Tgf-β, Col1a1, Col4a1, Pdgfb, Mmp1, Mmp2, and Timp1) induced in LX2 hepatic stellate cells by TGF-β1, and the whole-cell expression and nucleus expression of fibrosis-related proteins (p-SMAD2, SMAD2, p-SMAD3, SMAD3, and SMAD4). In addition, the jujube polysaccharide-containing composition can significantly suppress body fat mass (fat mass (g), adiposity (% fat)) increased by a high-fat, high-fructose diet (HFHFD), and significantly reduce hepatic steatosis and inflammation. Therefore, the jujube polysaccharide-containing composition according to the present invention is expected to be advantageously used as an anti-fibrotic composition for preventing, alleviating, and treating fatty liver or liver cirrhosis.
Need to check novelty before this filing date? Find Prior Art